SCHEMBL14239759

SCHEMBL14239759

CCOc1cccc(OCCN(C)C)c1C(=O)Nc1ccc(Cl)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.46
MCHR1 Q99705 1/20 0.45
PTPN1 P18031 1/20 0.44
LMNA P02545 1/20 0.44
NPC1 O15118 2/20 0.44
TSHR P16473 2/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
RORC P51449 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPK14 Q16539 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18804903 0.92 KDR (0.52) KDRMCHR1PTPN1LMNANPC1
SCHEMBL19799133 0.91 KDR (0.50) KDRSMN1; SMN2MCHR1LMNANPC1
SCHEMBL18804895 0.86 KDR (0.47) KDRMCHR1NPC1RXFP1RORC
SCHEMBL19799089 0.86 KDR (0.53) KDRMCHR1LMNANPC1TSHR
SCHEMBL19052107 0.86 CSF1R (0.44) KDRSMN1; SMN2LMNANPC1RORC
SCHEMBL9951429 0.86 RXFP1 (0.49) KDRSMN1; SMN2LMNARXFP1RAB9A
SCHEMBL29677914 0.86 RXFP1 (0.49) KDRSMN1; SMN2LMNARXFP1RAB9A
SCHEMBL31376514 0.86 RXFP1 (0.49) KDRSMN1; SMN2LMNARXFP1RAB9A
SCHEMBL19799125 0.86 KDR (0.53) KDRSMN1; SMN2MCHR1LMNANPC1
SCHEMBL22339753 0.86 HRH3 (0.56) KDRSMN1; SMN2MCHR1PTPN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165813-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-06-01 US disclosed
US-9969677-B2 Histone acetyltransferase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-05-15 US disclosed
US-20170121276-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-05-04 US disclosed
WO-2012171008-A1 USES OF HISTONE ACETYLTRANSFERASE ACTIVATORS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121276-A1 HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF EP300, KAT2A, HTT KDR 4841/4885SMN1; SMN2 817/4885MCHR1 3612/4885
US-20230165813-A1 HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF HDAC6, HDAC9, HDAC5 KDR 4817/4885SMN1; SMN2 437/4885MCHR1 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.